Andrew Butcher is speaking on “Balancing cost effectiveness with economics – alleviate funding constraints on HTA approved drugs by managing diverging stakeholder perspectives.” CRA is also sponsoring the conference.
For more information on the event, click here.
CRA leading the way in analytics
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...